EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Celvapan

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion / Notification [1] issued on	Commission Decision issued [2] / amended on	Product Information affected [3]	Summary
T/0031	Transfer of Marketing Authorisation	05/11/2015	30/11/2015	SmPC, Labelling and PL	
PSUSA/2280/ 201410	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (h1n1) (whole virion inactivated, prepared in cell culture)	11/06/2015	n/a		PRAC Recommendation - maintenance
R/0029	Renewal of the marketing authorisation.	26/02/2015	06/05/2015	Annex II	Based on the review of available information, the CHMP is of

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact

					the opinion that the quality, safety and efficacy of Celvapan continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable. The CHMP recommends that the renewal be granted with unlimited validity.
PSUV/0027	Periodic Safety Update	13/06/2014	n/a		PRAC Recommendation - maintenance
N/0028	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	26/05/2014	19/06/2014	PL	
IAIN/0026	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	21/06/2013	19/06/2014	SmPC, Annex II and PL	
II/0024	Change to analytical method used during the manufacture of the active substance. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS	30/05/2013	n/a		
IB/0023	B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method	05/03/2013	n/a		
IA/0022	A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding	16/10/2012	n/a		

	manufacturer for batch release)				
II/0019/G	This was an application for a group of variations. Update of sections 4.2, 4.6, 4.8 and 5.1 of the SmPC to reflect the results on immunogenicity and safety from the pandemic observational study 820901 and the paediatric study 820903. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to include minor amendments in the SmPC and Labelling. Furthermore, the PI is being brought in line with the latest QRD template version 8.1. Some of the obligations (Conditions to the Marketing Authorisation) have been deleted from the Annex II as fulfilled. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH	21/06/2012	26/07/2012	SmPC, Annex II, Labelling and PL	Please refer to the assessment report: Celvapan-H-9[illegible]-II-19-G-AR
IB/0020	B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product as packaged for sale	18/06/2012	26/07/2012	SmPC	

IA/0021	A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS	15/05/2012	n/a		
IB/0018	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Extension of storage period of a biological/immunological medicinal product in accordance with an approved stability protocol	22/06/2011	n/a	SmPC, Annex II and PL	
II/0017/G	This was an application for a group of variations. Group of 5 type II variations (C.I.4) to update of sections 4.8 and 5.1 of the SmPC further to the evaluation of clinical follow-up measures (FUMs 30, 38, 39 & 40) and of the PSUR covering the period from 6 October 2009 to 30 September 2010 as requested by the CHMP. The section 4 of the PL has been updated accordingly. The MAH took the opportunity to correct mistakes in section 4.2 and 4.6 of the SmPC and to update the contact details for Latvia in the PL. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical,	14/04/2011	18/05/2011	SmPC, Annex II and PL	Please refer to the assessment report: Celvapan-H-982-II-17-G-AR

	clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data				
SW/0014	Switch from conditional to full Marketing Authorisation	22/04/2010	12/08/2010	SmPC, Annex II, Labelling and PL	
II/0013	Update of section 4.8 of the SmPC to reflect safety data of SO2 028.4 (abridged report for post-dose 2 safety and immunogenicity data from paediatric H1N1 study 820903), S-PSUR 4 and preliminary data from observational study 820901. The Package Leaflet has been updated accordingly. In addition the MAH took this opportunity to update the PI to reflect safety data of SO2 027.2 (abridged report for post-dose 2 safety and immunogenicity data from adult H1N1 study 820902). Annex II has also been updated to reflect the current status of the specific obligations. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH	18/03/2010	05/07/2010	SmPC, Annex II and PL	Please refer to the assessment report: Celvapan-H-982-II-13-AR
II/0007	Update of sections 4.2 and 5.1 of the SmPC based clinical study results (820903) with Celvapan containing 7.5µg H1N1 antigen of the A/H1N1/California/07/2009 influenza virus in infants,	18/03/2010	05/07/2010	SmPC and PL	Please refer to the assessment report: Celvapan-H-982-II-07-AR

	children and adolescent aged 6 months to 17 years. Section 3 of the PL has been updated accordingly. Update of Summary of Product Characteristics and Package Leaflet				
II/0005	Update of sections 4.2 and 5.1 of the SmPC based clinical study results (study 920902) with Celvapan containing 7.5µg H1N1 antigen of the A/H1N1/California/07/2009 influenza virus in adults and elderly. The PL has been updated accordingly. Update of Summary of Product Characteristics and Package Leaflet	18/03/2010	05/07/2010	SmPC and PL	Please refer to the assessment report: Celvapan-H-982-II-05-AR
II/0012	Update of section 4.8 of the SmPC based on the 2nd S-PSUR for Celvapan covering the period 17.11.09 - 14.12.09. Consequently the PL was updated. In addition the MAH took this opportunity to update Annex II to reflect the current status of the specific obligations and contact details of local representatives in the PL. Update of Summary of Product Characteristics and Package Leaflet	18/03/2010	30/03/2010	SmPC, Annex II and PL	Please refer to the scientific discussion: Celvapan-H-982-II-12-AR
II/0008	Update of the Detailed Description of the Pharmacovigilance System (DDPS) to reflect outsourcing of services to a CRO during a declared pandemic and additional Celvapan specific procedures. Consequently, Annex II has been updated with the new version number of the agreed DDPS.	18/02/2010	30/03/2010	Annex II	The DDPS has been updated to version 1.20-2-Celvapan to reflect the changes. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. The CHMP considers that the Pharmacovigilance System as described by the MAH fulfils the requirements.

	Update of DDPS (Pharmacovigilance)				
II/0010	To introduce changes in the purification II process of the drug substance. Quality changes	18/02/2010	05/03/2010		
II/0011	To introduce an alternative manufacturing site for formulation of the finished product. Quality changes	21/01/2010	09/02/2010		
II/0009	Update of sections 4.2, 4.4 and 4.8 of the SmPC to reflect safety information available with Celvapan containing the A/H1N1/California/07/2009 influenza virus in adults (including the elderly). Annex II and sections 2 and 4 of the PL have been updated accordingly. Update of Summary of Product Characteristics and Package Leaflet	17/12/2009	22/12/2009	SmPC, Annex II and PL	Please refer to the scientific discussion: Celvapan-H-982-II-09-AR
II/0006	To update sections 4.8 of the SmPC to reflect safety results of H1N1 studies in children and in adults as requested by the CHMP. Annex II and the PL were updated accordingly. Update of Summary of Product Characteristics and Package Leaflet	22/10/2009	11/11/2009	SmPC, Annex II and PL	Please refer to the Public assessment report. (Celvapan-H-982-II-06-AR)
II/0004	To introduce an additional filing site for the Drug product	22/10/2009	28/10/2009		

	Quality changes				
II/0003	To increase the batch size of the final Drug Product. Quality changes	22/10/2009	28/10/2009		
PU/0002	The MAH applied to update the vaccine strain in Celvapan from H5N1 to the Pandemic strain H1N1 (A/California/7/2009 (H1N1)v). Pandemic Update	01/10/2009	06/10/2009	SmPC, Annex II, Labelling and PL	
II/0001	Update of sections 4.6 and 5.3 of the SmPC to reflect results of two reproductive and developmental toxicology studies in the rat. The MAH took the opportunity to introduce corrections in the labelling and Annex II. The wording in Annex II regarding PSUR requirements during a pandemic was revised. The list of local representatives in the PL was updated for Cyprus, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Norway, Romania, Slovenia and Sweden. Update of Summary of Product Characteristics, Labelling and Package Leaflet	23/07/2009	27/08/2009	SmPC, Annex II, Labelling and PL	Two rat studies were conducted to assess the effect of an H5N1 vaccine and vaccine-specific antibodies on reproduction and development. The responses to the vaccine and exposure of fetuses to specific antibodies in rats did not elicit vaccine-related harmful effects on mating performance or female fertility, embryo-foetal survival and pre- and post-natal development. The product information was updated to reflect this.